As an asset manager owned by one of the UK’s largest insurers, we have a vast amount of experience in fixed income. This ranges from developed and emerging market bonds, to investment grade and high yield.
Our heritage predisposes us to managing risk and focusing on downside protection. As well as offering pooled solutions, we offer bespoke solutions to cater to complex and sophisticated institutional and wholesale client needs.
Strategies in focus
Emerging market debt
A range of emerging market debt strategies that invest across hard and local currency markets.
Investment grade credit
A range of strategies that utilise portfolio construction to deliver attractive returns throughout the credit cycle.
A range of strategies that aim to capture the full potential of high yield bond markets while protecting to the downside.
A range of strategies offering the potential for uncorrelated returns, portfolio diversification and low volatility in either a long-only or absolute return context.
Climate Transition Credit
A strategy seeking long-term, consistent excess returns and positive climate outcomes.
A strategy that aims to enhance returns on cash by investing in short-maturity, highly rated fixed-income securities where T+0 liquidity is deemed unnecessary.
Hitting the yield sweet spot: Opportunities in short-duration credit
With the interest-rate cycle turning sharply, we explain why cash and fixed income investors may wish to consider the tactical and strategic attractions of short-duration credit.
A decade on: Lessons for short-duration global high-yield bond investors
To mark the ten-year anniversary of the Aviva Investors Short Duration Global High Yield Bond Strategy, Sunita Kara and Josh Panton explain why the asset class could be a solution for fixed-income investors in a fast-changing market.
Use your influence: Overcoming the challenges of sovereign engagement
We explore the challenges and opportunities for investors engaging with sovereign debt issuers.
A talented team of investors
Chief Investment Officer, Liquid Markets
Head of Credit
Head of Emerging Market Debt and Portfolio Manager, EM Local Currency
James Vokins, CFA
Global Head of Investment Grade Credit
Head of Global Buy-and-Maintain, Credit
Global Co-Head of High Yield
Global Co-Head of High Yield
Need more information?
For further information, please contact our investment sales team.
Fixed income views
What does the data say? Are we close to 1970’s-style stagflation?
29 Jul 2022
In this month’s instalment of our visual series on topical themes, we look at whether the global economy is heading towards stagflation.
Convertible bonds: Five questions with David Clott
19 Jul 2022
In the first of a new series, David Clott assesses the key recent developments in the convertible bond market and outlines why this could be an attractive entry point into the asset class with Rico Pedrett.
Bumpy ride set to continue for credit investors
18 Jul 2022
The co-managers of the Aviva Investors Strategic Bond strategy give their views on the outlook for credit markets following the worst first-half in at least 40 years.
The AIQ Podcast: Taking stock of nature risk
15 Jul 2022
The idea that human actions are bringing natural systems close to breakdown, threatening livelihoods and financial stability, is making asset managers think harder about nature risk and the environmental dependencies in investee companies.
EMD: On the bread line
6 Jul 2022
Russia’s war in Ukraine has contributed to soaring food prices, supercharging global inflation. Poorer countries will likely be hardest hit, adding to the risk of social unrest. With public finances and incomes already under strain, emerging-market debt investors should be on high alert.
Inflation, volatility and default risk: The outlook for high yield
13 Jun 2022
The co-heads of our global high yield team explain how the asset class is standing up to current headwinds.
Conflict, commodities and China: The outlook for EMD
13 May 2022
Aaron Grehan and Nafez Zouk from our emerging market debt team explain how the asset class is standing up to some significant headwinds.
Game over for Zambia? A test case for debt restructuring
12 Apr 2022
The economic fallout from the pandemic has left several poorer nations struggling to repay debt. China, the biggest single creditor to many, could carry considerable clout in negotiations. Zambia will prove an early test case, argues Carmen Altenkirch.
What does the data say? Credit in focus
31 Mar 2022
In this month’s instalment of our visual series on topical themes, we look at key trends in the credit market.
Now for the hard part…..The challenge of delivering net zero
29 Mar 2022
More than one fifth of the world’s largest listed companies have committed to net-zero targets, but few have detailed roadmaps to get there. Mirza Baig considers the challenges for investors managing transition pathways.
No time for heroes: How portfolio construction can help investors navigate unfamiliar economic and market regimes
22 Mar 2022
We are back in an old, but unfamiliar market regime. In a period where simple playbooks may falter, Jeremy Albers sets out why portfolio construction can make the difference.
Russia-Ukraine update: The ten key questions for EMD investors
18 Mar 2022
We assess the near and longer-term implications of Russia’s invasion of Ukraine on emerging-market debt.
How bond investors can influence companies and governments to change their behaviour for the better
17 Mar 2022
Bondholders are starting to use their power to influence corporate behaviour in areas such as climate change, social inequality and biodiversity loss.
China, inflation and politics: Three reasons for EM turbulence
24 Feb 2022
Emerging market assets have underperformed developed market peers over the past decade. While this has led to valuation gaps, selectivity will be critical, argues David Nowakowski.
Untapped potential: Harnessing the full power of bondholder engagement
31 Jan 2022
Investor influence has long been confined to that of equity shareholders. Yet bondholders wield a lot of power. Can they harness it for positive change?
The future of pharma: Increased returns or the age of biotech?
8 Dec 2021
After decades of low returns on research and development (R&D), the healthcare sector is producing a slew of innovations, from drugs to diagnostics. But with many coming from new entrants, will big pharmaceutical companies manage to keep up with the times?